Black Health

Sickle Cell Disease

Sickle cell comprehensive care centers, state by state

Roughly 100,000 Americans live with sickle cell disease, and roughly 90% are Black or African-American. The U.S. has the care infrastructure — NHLBI-funded comprehensive centers, universal newborn screening, four FDA-approved disease-modifying therapies, and as of December 2023 two FDA-approved CRISPR gene therapies — but the infrastructure is unevenly distributed and Black patients still face the sharpest edges of care-access inequity: the 18-30 transition gap, undertreated pain crises in the emergency department, and Medicaid coverage variation for the new gene therapies.

These pages document every comprehensive sickle cell care center we can verify, every state's SCDAA chapter + Medicaid coverage status, and plain-language explainers of the topics SCD families actually search for.

~100,000 Americans live with SCD · ~90% Black 98 comprehensive centers documented NHLBI-SCDIC + SCDAA + CDC SCDC sourced

Topic guides

Comprehensive centers

What a Sickle Cell Comprehensive Care Center Actually Is — and How to Find One

A comprehensive SCD center brings hematology, pain management, transfusion services, stem-cell transplant, behavioral health, and transition-of-care under one roof.

Read

Newborn screening

Sickle Cell Newborn Screening — Every State Screens, What Happens Next

Every U.S. state has screened newborns for sickle cell disease since 2006, and early identification lets families start penicillin prophylaxis by two months old.

Read

Treatments

Sickle Cell Disease Treatments — Hydroxyurea to CRISPR Gene Therapy

Current FDA-approved sickle cell treatments include hydroxyurea, L-glutamine (Endari), voxelotor (Oxbryta), crizanlizumab (Adakveo), and the two CRISPR gene therapies approved in …

Read

Adult transition

The Sickle Cell Adolescent-to-Adult Transition — Where Mortality Peaks

The transition from pediatric to adult sickle cell care between ages 18 and 30 is the single highest-mortality window in SCD — a gap driven by care fragmentation, insurance churn,…

Read

ER pain crisis

Sickle Cell Pain Crisis in the ER — How to Advocate for Proper Treatment

Sickle cell pain crises are routinely undertreated in emergency departments: Black patients with SCD wait longer for analgesia and are more often suspected of drug-seeking behavio…

Read

Clinical trials

Active Sickle Cell Clinical Trials Recruiting Black Patients

More than 400 active SCD clinical trials are listed at ClinicalTrials.gov — including the post-approval confirmatory trials for Casgevy and Lyfgenia, next-generation gene-editing …

Read

Find resources in your state

Alabama

SCDAA of North Central Alabama

NHLBI SCDIC ~4,200 patients

Alaska

No SCDAA chapter

Arizona

SCDAA of Arizona

~1,400 patients

Arkansas

Sickle Cell Support Services of Arkansas

~1,500 patients

California

Cayenne Wellness Center (SCDAA of California)

NHLBI SCDIC CRISPR covered ~8,300 patients

Colorado

Sickle Cell Treatment and Research Center (Colorado)

CRISPR pending ~550 patients

Connecticut

Citizens for Quality Sickle Cell Care (CT)

~1,100 patients

Delaware

SCDAA of Delaware Valley

~650 patients

Florida

Sickle Cell Disease Association — Florida

NHLBI SCDIC ~7,500 patients

Georgia

SCDAA — Atlanta

NHLBI SCDIC CRISPR covered ~9,200 patients

Hawaii

No SCDAA chapter

Idaho

No SCDAA chapter

Illinois

SCDAA — Illinois

NHLBI SCDIC CRISPR covered ~5,200 patients

Indiana

Martin Center Sickle Cell Initiative

~1,600 patients

Iowa

No SCDAA chapter

~250 patients

Kansas

Uriel E. Owens Sickle Cell Disease Association (KS/MO)

~500 patients

Kentucky

SCDAA — Kentuckiana

~850 patients

Louisiana

SCDAA — Louisiana Chapter

NHLBI SCDIC ~3,800 patients

Maine

No SCDAA chapter

Maryland

SCDAA — National Capital Area

NHLBI SCDIC CRISPR covered ~3,900 patients

Massachusetts

SCDAA — Boston (New England Region)

NHLBI SCDIC CRISPR covered ~1,900 patients

Michigan

SCDAA of Michigan

NHLBI SCDIC CRISPR pending ~3,900 patients

Minnesota

Sickle Cell Foundation of Minnesota

~950 patients

Mississippi

Mississippi SCDAA Chapter

~3,300 patients

Missouri

SCDAA of Greater St. Louis

NHLBI SCDIC ~2,100 patients

Montana

No SCDAA chapter

Nebraska

Sickle Cell Disease Foundation of Nebraska

~300 patients

Nevada

Nevada Sickle Cell Foundation

~750 patients

New Hampshire

No SCDAA chapter

New Jersey

SCDAA — New Jersey Chapter

NHLBI SCDIC CRISPR covered ~3,400 patients

New Mexico

No SCDAA chapter

New York

Sickle Cell Thalassemia Patients Network (NYC)

NHLBI SCDIC CRISPR covered ~10,200 patients

North Carolina

SCDAA — Piedmont Chapter (NC)

NHLBI SCDIC CRISPR covered ~5,100 patients

North Dakota

No SCDAA chapter

Ohio

SCDAA — Northwest Ohio (and Central Ohio chapter)

NHLBI SCDIC CRISPR covered ~3,700 patients

Oklahoma

Supporters of Families with Sickle Cell Disease (Oklahoma)

~1,200 patients

Oregon

Sickle Cell Anemia Foundation of Oregon

~400 patients

Pennsylvania

SCDAA — Philadelphia / Delaware Valley

NHLBI SCDIC CRISPR covered ~4,400 patients

Rhode Island

No SCDAA chapter

~200 patients

South Carolina

James R. Clark Memorial Sickle Cell Foundation

NHLBI SCDIC ~2,900 patients

South Dakota

No SCDAA chapter

Tennessee

Sickle Cell Foundation of Tennessee

NHLBI SCDIC CRISPR covered ~3,200 patients

Texas

SCDAA — East Texas (Houston)

NHLBI SCDIC CRISPR pending ~7,600 patients

Utah

No SCDAA chapter

~250 patients

Vermont

No SCDAA chapter

Virginia

SCDAA — Central Virginia

NHLBI SCDIC CRISPR covered ~3,100 patients

Washington

Central City Sickle Cell Foundation (WA)

CRISPR covered ~850 patients

West Virginia

No SCDAA chapter

~400 patients

Wisconsin

SCDAA — Wisconsin

~1,100 patients

Wyoming

No SCDAA chapter

District of Columbia

SCDAA — National Capital Area

NHLBI SCDIC CRISPR covered ~1,800 patients

Full directory

Browse every comprehensive care center

Filter by state, pediatric vs. adult, transition program, and CRISPR gene-therapy availability.

Center directory

Methodology & data sources

Center inclusion: NHLBI Sickle Cell Disease Implementation Consortium (SCDIC) member sites; authorized Casgevy (exa-cel) and Lyfgenia (lovo-cel) treatment centers publicly listed by Vertex Pharmaceuticals and bluebird bio; SCDAA chapter-affiliated pediatric and adult clinics; major academic children's hospitals with a documented pediatric hematology SCD program. Records with missing address or phone render a stub page and are excluded from sitemap indexing until the data is filled in.

State data: SCDAA chapter directory (sicklecelldisease.org/chapters), CDC Sickle Cell Data Collection program (11 participating states publish claims-based prevalence), NHLBI modeling, Baby's First Test newborn-screening panel lookup, and KFF 50-state tracker of Medicaid gene-therapy coverage.

Refresh cadence: quarterly for center rosters + Medicaid CRISPR coverage, weekly for ClinicalTrials.gov snapshots.

Data refreshed: